CYP2E1 genotyping in renal cell/urothelial cancer patients in comparison with control populations

International Journal of Clinical Pharmacology and Therapeutics

Volumn 36, Issue 9, 1998, Pages 463-468

  Farker, K ^a   Lehmann, M H ^a   Kastner R ^a   Hoffmann, A ^a   Janitzky, V ^a   Schubert, J ^a   Matz, U ^b   Hofmann, W ^b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

CYP2E1; Cytochrome P450; Polymorphism; Renal cell and urothelial cancer

Indexed keywords

CARCINOGEN; CYTOCHROME P450 ISOENZYME; RESTRICTION ENDONUCLEASE;

ARTICLE; CANCER GENETICS; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DNA DETERMINATION; DRUG METABOLISM; ENZYME INDUCTION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GERMANY; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; HUMAN CELL; INTRON; KIDNEY CANCER; KIDNEY CELL; LEUKOCYTE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; UROGENITAL TRACT TUMOR;

CARCINOMA, RENAL CELL; CYTOCHROME P-450 CYP2E1; GENOTYPE; HUMANS; KIDNEY NEOPLASMS; POLYMORPHISM, GENETIC; RISK FACTORS; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 0031709157     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Anwar WA, Abdel-Rahmen SZ, El-Zein RA, Mostafa HM, Au WW 1996 Genetic polymorphism of GSTM1 CYP2E1 and CYP2D6 in Egyptian bladder cancer patients. Carcinogenesis 17: 1923-1929
2. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW 1993 Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 85: 1159-1164
3. Brockmöller J, Cascorbi I, Roots I 1996 Gene-environment synergisms in bladder cancer risk: arylamine N-acetyltransferase type 2 smoking and occupation. Int J Clin Pharmacol Ther 34: 321
4. Brockmöller J, Kerb R, Drakoulis N, Staffeldt B, Roots I 1994 Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: a case-control study. Cancer Res 54: 4103-4111
5. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling A, Roots I 1995 Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 57: 581-592
6. Craddock VM 1983 Nitrosamines and human cancer: proof of an association. Nature 306: 638
7. Drakoulis N, Cascorbi I, Brockmöller CR, Roots I 1994 Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G) and a T to C mutation in the 3′-flanking region. Clin Invest 72: 240-248
8. Farker K, Vogt S, Janitzky V, Matz U, Hoffmann A, Schubert J 1996 CYP1A1 polymorphism - no risk factor for kidney and urothelial cancer. Exp Toxicol Pathol 48 (Suppl II): 113-116
9. Farker K, Vogt S, Schlichter A, Matz U, Janitzky V, Schubert J, Hoffmann A 1996 Acetylation genotype (NAT2) in kidney and urothel cancer patients in Middle Germany. Pharmacoepidemiol Drug Saf 5: S28
10. Guengerich FP 1988 Roles of cytochrome P450 enzymes in chemical carcinogenes and cancer chemotherapy. Cancer Res 48: 2946-2954
11. Guengerich FP, Kim DH, Iwasaki M 1991 Role of human cytochrome P450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 4: 168-179
12. Hayashi SI, Watanabe J, Kawajiri K 1991 Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem 110: 559-565
13. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Vainio H 1993 The human CYP2E1 gene and lung cancer: DraI and RsaI restriction fragment length polymorphism in a Finnish study. Carcinogenesis 14: 85-88
14. Hong J, Yang CS 1985 The nature of microsomal N-nitrosodimethylamine demethylase and its role in carcinogen activation. Carcinogens 6: 1805-1809
15. Ingelmann-Sundberg M, Johansson I 1984 Mechanisms of hydroxyl radical formation of ethanol oxidation by ethanol-inducible and other forms of rabbit liver microsomal cytochromes P-450. J Biol Chem 259: 6447-6458
16. Johansson I, Ingelman-Sundberg M 1985 Carbon tertrachloride-induced lipid peroxidation dependent on an ethanol-inducible form of rabbit liver microsomal cytochrome P450. FEBS Lett 183: 265-269
17. Kato S, Shields PG, Caporaso NE, Hoover RN, Trump BF, Sugimura H, Weston A, Harris CC 1992 Cytochrome P450IIE1 genetic polymorphisms racial variations and lung cancer risk. Cancer Res 52: 6712-6715
18. Kato S, Shields PG, Caporaso NE, Sugimura H, Trivers GE, Tucker MA, Trump BF, Weston A, Harris CC 1994 Analysis of cytochrome P450 2E1 genetic polymorphisms in relation to human lung cancer. Cancer Epidemiol Biomarkers Prev 3: 515-518
19. Kempkes M, Golka K, Reich S, Reckwitz T, Bolt HM 1996 Glutathione S-transferase GSTM1 and GSTT1 null genotypes as potential risk factors for urothelial cancer of the bladder. Arch Toxicol 71: 123-126
20. Maezawa Y, Yamauchi M, Toda G 1994 Association between restriction fragment length polymorphisms of the human cytochrome P450IIE1 gene and susceptibility to alcoholic liver cirrhosis. Am J Gastroenterol 89: 561-565
21. Nakachi K, Imai K, Hayashi SI, Kawajiri K 1993 Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res 53: 2994-2999
22. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW 1996 P450 superfamily: update on new sequences gene mapping accession numbers and nomenclature. Pharmacogenetics 6: 1-42
23. Oyama T, Kawamoto T, Mizoue T, Sugio K, Kodama Y, Mitsudomi T, Yasumoto K 1997 Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer: in relation to p53 gene mutation. Anticancer Res 17: 583-587
24. O'Neill IK, Chen J, Bartsch H 1991 Relevance to human cancer of N-nitroso compounds tobacco and mycotoxins. Publication no. 105. International Agency for Research on Cancer, Lyon
25. Raunio H, Husgafvel-Pursiainen K, Anttila S, Hietanen E, Hirvonen A, Pelkonen O 1995 Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility - a review. Gene 159: 113-121
26. Shields PG, Ambrosone CB, Graham S, Bowman ED, Harrington AM, Gillenwater KA, Marshall JR, Vena JE, Laughlin R, Nemoto T, Freudenheim JL 1996 A cytochrome P4502E1 genetic polymorphism and tobacco smoking in breast cancer. Mol Carcinog 17: 144-50
27. Sivaraman L, Leatham MP, Yee J, Wilkens LR, Lau AF, Marchand LL 1994 Cyp 1A1 genetic polymorphisms and in situ colorectal cancer. Cancer Res 54: 3692-3695
28. Tsutsumi M, Matsuda Y, Takada A 1993 Role of ethanol-inducible cytochrome P-450 2E1 in the development of hepatocellular carcinoma by the chemical carcinogen N-nitrosodemethylamine. Hepatology 18: 1483-1489
29. Uematsu F, Kikuchi H, Motomiya M, Abe T, Sagami I, Ohmachi T, Wakui A, Kanamaru R, Watanabe M 1991 Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer. Jpn J Cancer Res 82: 254-256
30. Yang CS, Yoo JS, Ishizaki H, Hong J 1990 Cytochrome P450IIE1: roles of nitrosamine metabolism and mechanism of regulation. Drug Metab Rev 22: 147-159